Global LFA-based Cardiac Market Size, Status and Forecast 2020-2026

SKU ID : QYR- 15558890

Publishing Date : 15-Apr-2020

No. of pages : 97

PRICE
3900
5850
7800

  • Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
    Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
    The industry's leading producers are Roche, Abbott and Siemens, with revenues of 26.24%, 16.11% and 11.04% respectively in 2019.
    Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the LFA-based Cardiac market in 2020.
    COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
    The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
    This report also analyses the impact of Coronavirus COVID-19 on the LFA-based Cardiac industry.
    Based on our recent survey, we have several different scenarios about the LFA-based Cardiac YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 3086.9 million in 2019. The market size of LFA-based Cardiac will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
    With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global LFA-based Cardiac market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global LFA-based Cardiac market in terms of revenue.
    Players, stakeholders, and other participants in the global LFA-based Cardiac market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
    Regional and Country-level Analysis
    The report offers an exhaustive geographical analysis of the global LFA-based Cardiac market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
    Competition Analysis
    In the competitive analysis section of the report, leading as well as prominent players of the global LFA-based Cardiac market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global LFA-based Cardiac market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global LFA-based Cardiac market.
    The following players are covered in this report:
    Roche
    Abbott
    Siemens
    Danaher
    Bio-Rad Laboratories
    BioMérieux
    Thermo Fisher
    Ortho Clinical Diagnostics
    LSI Medience Corporation
    Randox laboratories
    Wondfo Biotech
    LFA-based Cardiac Breakdown Data by Type
    Troponin I
    Troponin T
    CK-MB
    Myoglobin
    Others
    LFA-based Cardiac Breakdown Data by Application
    Laboratory Testing
    Point-of-care Testing

    Frequently Asked Questions



    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports